{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T12:01:28Z","timestamp":1793275288436,"version":"4.5.0"},"reference-count":64,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Swedish Governmental Funding for clinical research","award":["43301"],"award-info":[{"award-number":["43301"]}]},{"DOI":"10.13039\/100008444","name":"Parkinsonfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008444","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr?det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s13311-018-00699-9","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T14:54:40Z","timestamp":1549983280000},"page":"465-479","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease"],"prefix":"10.1016","volume":"16","author":[{"given":"Veronica","family":"Francardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Geva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilach","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Hayden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angela","family":"Cenci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1007\/s13311-018-00699-9_bib1","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1016\/j.cell.2007.08.036","article-title":"Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival","volume":"131","author":"Hayashi","year":"2007","journal-title":"Cell."},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/156720206776875849","article-title":"Sigma receptor activation reduces infarct size at 24 hours after permanent middle cerebral artery occlusion in rats","volume":"3","author":"Ajmo","year":"2006","journal-title":"Current Neurovascular Research"},{"issue":"4","key":"10.1007\/s13311-018-00699-9_bib3","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1161\/01.STR.31.4.976","article-title":"Sigma(1)-receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion","volume":"31","author":"Harukuni","year":"2000","journal-title":"Stroke."},{"issue":"9","key":"10.1007\/s13311-018-00699-9_bib4","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/npp.2013.70","article-title":"Blockade of Tau hyperphosphorylation and Abeta(1)(\u2212)(4)(2) generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and sigma(1) receptor agonist, in a nontransgenic mouse model of Alzheimer's disease","volume":"38","author":"Lahmy","year":"2013","journal-title":"Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology."},{"issue":"4","key":"10.1007\/s13311-018-00699-9_bib5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s13311-012-0140-y","article-title":"Sigma-1R agonist improves motor function and motoneuron survival in ALS mice","volume":"9","author":"Mancuso","year":"2012","journal-title":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics."},{"issue":"8","key":"10.1007\/s13311-018-00699-9_bib6","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1093\/hmg\/ddt008","article-title":"Altered localization, abnormal modification and loss of function of Sigma receptor-1 in amyotrophic lateral sclerosis","volume":"22","author":"Prause","year":"2013","journal-title":"Human molecular genetics."},{"issue":"9","key":"10.1007\/s13311-018-00699-9_bib7","doi-asserted-by":"crossref","first-page":"e45118","DOI":"10.1371\/journal.pone.0045118","article-title":"Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke","volume":"7","author":"Ruscher","year":"2012","journal-title":"PloS one."},{"issue":"Pt 3","key":"10.1007\/s13311-018-00699-9_bib8","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/brain\/awq367","article-title":"The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke","volume":"134","author":"Ruscher","year":"2011","journal-title":"Brain : Journal of Neurology."},{"issue":"8","key":"10.1007\/s13311-018-00699-9_bib9","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0269881110379286","article-title":"Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma 1 (sigma1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative","volume":"25","author":"Villard","year":"2011","journal-title":"Journal of Psychopharmacology."},{"issue":"5","key":"10.1007\/s13311-018-00699-9_bib10","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1089\/neu.2010.1674","article-title":"Sigma receptor agonist 2-(4-morpholinethyl)1 phenylcyclohexanecarboxylate (Pre084) increases GDNF and BiP expression and promotes neuroprotection after root avulsion injury","volume":"28","author":"Penas","year":"2011","journal-title":"Journal of Neurotrauma."},{"key":"10.1007\/s13311-018-00699-9_bib11","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neurobiolaging.2017.08.007","article-title":"Sigma-1 receptor knockout increases alpha-synuclein aggregation and phosphorylation with loss of dopaminergic neurons in substantia nigra","volume":"59","author":"Hong","year":"2017","journal-title":"Neurobiology of Aging."},{"issue":"5","key":"10.1007\/s13311-018-00699-9_bib12","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1002\/mds.27360","article-title":"Disease modification in Parkinson's disease: current approaches, challenges, and future considerations","volume":"33","author":"Lang","year":"2018","journal-title":"Movement disorders : Official Journal of the Movement Disorder Society."},{"issue":"Pt B","key":"10.1007\/s13311-018-00699-9_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.expneurol.2017.10.001","article-title":"Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease","volume":"298","author":"Francardo","year":"2017","journal-title":"Experimental Neurology."},{"issue":"3","key":"10.1007\/s13311-018-00699-9_bib14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.nbd.2009.11.004","article-title":"Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention","volume":"37","author":"Tansey","year":"2010","journal-title":"Neurobiology of Disease."},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3233\/JPD-140491","article-title":"Role of alpha-synuclein in inducing innate and adaptive immunity in Parkinson disease","volume":"5","author":"Allen Reish","year":"2015","journal-title":"Journal of Parkinson's Disease."},{"issue":"4","key":"10.1007\/s13311-018-00699-9_bib16","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.bbrc.2016.08.168","article-title":"Calcium and Parkinson's disease","volume":"483","author":"Surmeier","year":"2017","journal-title":"Biochemical and Biophysical Research Communications."},{"issue":"Pt 7","key":"10.1007\/s13311-018-00699-9_bib17","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/brain\/awu107","article-title":"Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism","volume":"137","author":"Francardo","year":"2014","journal-title":"Brain : A Journal of Neurology."},{"issue":"6","key":"10.1007\/s13311-018-00699-9_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s00702-008-0038-3","article-title":"Effects of (\u2212)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization","volume":"115","author":"Rung","year":"2008","journal-title":"Journal of Neural Transmission."},{"issue":"1\u20133","key":"10.1007\/s13311-018-00699-9_bib19","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.07.023","article-title":"In vivo pharmacology of the dopaminergic stabilizer pridopidine","volume":"644","author":"Ponten","year":"2010","journal-title":"European Journal of Pharmacology."},{"issue":"12","key":"10.1007\/s13311-018-00699-9_bib20","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1474-4422(11)70233-2","article-title":"Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"de Yebenes","year":"2011","journal-title":"The Lancet Neurology."},{"issue":"3","key":"10.1007\/s13311-018-00699-9_bib21","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/WNF.0b013e31821c31d8","article-title":"Regional cerebral glucose metabolism after pridopidine (ACR16) treatment in patients with Huntington disease","volume":"34","author":"Esmaeilzadeh","year":"2011","journal-title":"Clinical Neuropharmacology."},{"issue":"10","key":"10.1007\/s13311-018-00699-9_bib22","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1002\/mds.25362","article-title":"A randomized, double-blind, placebo-controlled trial of pridopidine in Huntington's disease","volume":"28","author":"Huntington Study Group HI","year":"2013","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society."},{"issue":"5","key":"10.1007\/s13311-018-00699-9_bib23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/WNF.0b013e3181ebb285","article-title":"Efficacy and safety of the dopaminergic stabilizer pridopidine (ACR16) in patients with Huntington's disease","volume":"33","author":"Lundin","year":"2010","journal-title":"Clinical Neuropharmacology."},{"key":"10.1007\/s13311-018-00699-9_bib24","doi-asserted-by":"crossref","unstructured":"Garcia-Miralles M, Geva M, Tan JY, Yusof N, Cha Y, Kusko R, et al. Early pridopidine treatment improves behavioral and transcriptional deficits in YAC128 Huntington disease mice. JCI Insight. 2017;2(23).","DOI":"10.1172\/jci.insight.95665"},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib25","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/mp.2012.3","article-title":"The dopamine stabilizers ACR16 and (\u2212)-OSU6162 display nanomolar affinities at the sigma-1 receptor","volume":"18","author":"Sahlholm","year":"2013","journal-title":"Molecular Psychiatry."},{"issue":"1\u20133","key":"10.1007\/s13311-018-00699-9_bib26","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejphar.2009.11.025","article-title":"The dopaminergic stabilizers pridopidine (ACR16) and (\u2212)-OSU6162 display dopamine D(2) receptor antagonism and fast receptor dissociation properties","volume":"628","author":"Dyhring","year":"2010","journal-title":"European Journal of Pharmacology."},{"issue":"18","key":"10.1007\/s13311-018-00699-9_bib27","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1007\/s00213-015-3997-8","article-title":"Pridopidine selectively occupies sigma-1 rather than dopamine D2 receptors at behaviorally active doses","volume":"232","author":"Sahlholm","year":"2015","journal-title":"Psychopharmacology."},{"issue":"3","key":"10.1007\/s13311-018-00699-9_bib28","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.nbd.2011.01.024","article-title":"Impact of the lesion procedure on the profiles of motor impairment and molecular responsiveness to L-DOPA in the 6-hydroxydopamine mouse model of Parkinson's disease","volume":"42","author":"Francardo","year":"2011","journal-title":"Neurobiology of Disease."},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib29","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1046\/j.0953-816x.2001.01843.x","article-title":"Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease","volume":"15","author":"Lundblad","year":"2002","journal-title":"The European Journal of Neuroscience."},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib30","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.expneurol.2009.05.017","article-title":"Stepping test in mice: a reliable approach in determining forelimb akinesia in MPTP-induced Parkinsonism","volume":"219","author":"Blume","year":"2009","journal-title":"Experimental Neurology."},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib31","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/exnr.1998.6916","article-title":"Intranigral transplants of GABA-rich striatal tissue induce behavioral recovery in the rat Parkinson model and promote the effects obtained by intrastriatal dopaminergic transplants","volume":"155","author":"Winkler","year":"1999","journal-title":"Experimental Neurology."},{"key":"10.1007\/s13311-018-00699-9_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.exer.2017.10.012","article-title":"Relationship between sigma-1 receptor and BDNF in the visual system","volume":"167","author":"Mysona","year":"2018","journal-title":"Experimental Eye Research."},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib33","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0166-2236(98)01362-9","article-title":"Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias","volume":"22","author":"West","year":"1999","journal-title":"Trends in Neurosciences."},{"issue":"37","key":"10.1007\/s13311-018-00699-9_bib34","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.1523\/JNEUROSCI.0944-06.2006","article-title":"Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia","volume":"26","author":"Westin","year":"2006","journal-title":"The Journal of Neuroscience : The Official Journal of the Society for Neuroscience."},{"issue":"13","key":"10.1007\/s13311-018-00699-9_bib35","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1523\/JNEUROSCI.20-13-05102.2000","article-title":"Striatal responses to partial dopaminergic lesion: evidence for compensatory sprouting","volume":"20","author":"Song","year":"2000","journal-title":"The Journal of Neuroscience : The Official Journal of the Society for Neuroscience."},{"issue":"6","key":"10.1007\/s13311-018-00699-9_bib36","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1460-9568.2002.01938.x","article-title":"Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging","volume":"15","author":"Cicchetti","year":"2002","journal-title":"The European Journal of Neuroscience."},{"issue":"5","key":"10.1007\/s13311-018-00699-9_bib37","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00281-013-0382-8","article-title":"Microglia and macrophages of the central nervous system: the contribution of microglia priming and systemic inflammation to chronic neurodegeneration","volume":"35","author":"Perry","year":"2013","journal-title":"Seminars in Immunopathology."},{"key":"10.1007\/s13311-018-00699-9_bib38","series-title":"The Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"2001"},{"key":"10.1007\/s13311-018-00699-9_bib39","doi-asserted-by":"crossref","unstructured":"Granado N, Ares-Santos S, Tizabi Y, Moratalla R. Striatal Reinnervation Process after Acute Methamphetamine-Induced Dopaminergic Degeneration in Mice. Neurotoxicity Research. 2018.","DOI":"10.1007\/s12640-018-9925-z"},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib40","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/S0306-4522(98)00217-6","article-title":"Biochemical and anatomical characterization of forepaw adjusting steps in rat models of Parkinson's disease: studies on medial forebrain bundle and striatal lesions","volume":"88","author":"Chang","year":"1999","journal-title":"Neuroscience."},{"issue":"1\u20132","key":"10.1007\/s13311-018-00699-9_bib41","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0006-8993(96)00519-7","article-title":"Skilled motor deficits in rats induced by ventrolateral striatal dopamine depletions: behavioral and pharmacological characterization","volume":"732","author":"Cousins","year":"1996","journal-title":"Brain Research."},{"issue":"7","key":"10.1007\/s13311-018-00699-9_bib42","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/syn.21549","article-title":"Sigma-1 receptor chaperones regulate the secretion of brain-derived neurotrophic factor","volume":"66","author":"Fujimoto","year":"2012","journal-title":"Synapse."},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib43","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/jnr.20713","article-title":"Glial cell line-derived neurotrophic factor promotes the arborization of cultured striatal neurons through the p42\/p44 mitogen-activated protein kinase pathway","volume":"83","author":"Garcia-Martinez","year":"2006","journal-title":"Journal of Neuroscience Research."},{"key":"10.1007\/s13311-018-00699-9_bib44","unstructured":"Svensson KA, Falcone JF, Johansson AM, Perry KW, MJ F, editors. The actions of the dopamine stabilizer ACR16, but not (\u2212)-OSU6162, in behavioral and neurochemical assays are not dependent on the presence of functional dopamine D2 receptors, 39th Annual Meeting, Society for Neuroscience; 2009; Chicago."},{"issue":"Pt A","key":"10.1007\/s13311-018-00699-9_bib45","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.nbd.2016.10.006","article-title":"The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease","volume":"97","author":"Ryskamp","year":"2017","journal-title":"Neurobiology of Disease."},{"issue":"18","key":"10.1007\/s13311-018-00699-9_bib46","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.1093\/hmg\/ddw238","article-title":"Pridopidine activates neuroprotective pathways impaired in Huntington Disease","volume":"25","author":"Geva","year":"2016","journal-title":"Human Molecular Genetics."},{"issue":"Pt 8","key":"10.1007\/s13311-018-00699-9_bib47","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1093\/brain\/awt192","article-title":"Disease duration and the integrity of the nigrostriatal system in Parkinson's disease","volume":"136","author":"Kordower","year":"2013","journal-title":"Brain : A Journal of Neurology."},{"issue":"12","key":"10.1007\/s13311-018-00699-9_bib48","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1007\/s11064-017-2379-5","article-title":"Neuroprotective Activities of Spirulina platensis in the 6-OHDA Model of Parkinson's Disease Are Related to Its Anti-Inflammatory Effects","volume":"42","author":"Lima","year":"2017","journal-title":"Neurochemical Research."},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib49","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12974-018-1266-6","article-title":"Vitamin D protects dopaminergic neurons against neuroinflammation and oxidative stress in hemiparkinsonian rats","volume":"15","author":"Lima","year":"2018","journal-title":"Journal of Neuroinflammation."},{"issue":"36","key":"10.1007\/s13311-018-00699-9_bib50","doi-asserted-by":"crossref","first-page":"9375","DOI":"10.1523\/JNEUROSCI.1636-16.2016","article-title":"Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model","volume":"36","author":"Tentillier","year":"2016","journal-title":"The Journal of Neuroscience : The Official Journal of the Society for Neuroscience."},{"key":"10.1007\/s13311-018-00699-9_bib51","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.biopha.2017.01.123","article-title":"Sesamin imparts neuroprotection against intrastriatal 6-hydroxydopamine toxicity by inhibition of astroglial activation, apoptosis and oxidative stress","volume":"88","author":"Baluchnejadmojarad","year":"2017","journal-title":"Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie."},{"issue":"7","key":"10.1007\/s13311-018-00699-9_bib52","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/glia.22496","article-title":"Doxycycline restrains glia and confers neuroprotection in a 6-OHDA Parkinson model","volume":"61","author":"Lazzarini","year":"2013","journal-title":"Glia."},{"key":"10.1007\/s13311-018-00699-9_bib53","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.brainres.2014.09.033","article-title":"Neuroprotection by 6-(methylsulfinyl)hexyl isothiocyanate in a 6-hydroxydopamine mouse model of Parkinsons disease","volume":"1589","author":"Morroni","year":"2014","journal-title":"Brain research."},{"key":"10.1007\/s13311-018-00699-9_bib54","doi-asserted-by":"crossref","first-page":"e1832","DOI":"10.1038\/cddis.2015.194","article-title":"Sigma-1 receptor deficiency reduces MPTP-induced parkinsonism and death of dopaminergic neurons","volume":"6","author":"Hong","year":"2015","journal-title":"Cell death & Disease."},{"issue":"8","key":"10.1007\/s13311-018-00699-9_bib55","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s00702-017-1825-5","article-title":"Animal models of L-DOPA-induced dyskinesia: the 6-OHDA-lesioned rat and mouse","volume":"125","author":"Tronci","year":"2018","journal-title":"Journal of Neural Transmission."},{"key":"10.1007\/s13311-018-00699-9_bib56","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.nbd.2013.10.010","article-title":"Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084, in a mouse model of motor neuron disease not linked to SOD1 mutation","volume":"62","author":"Peviani","year":"2014","journal-title":"Neurobiology of Disease."},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib57","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharmthera.2009.07.001","article-title":"The pharmacology of sigma-1 receptors","volume":"124","author":"Maurice","year":"2009","journal-title":"Pharmacology & Therapeutics."},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib58","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/jpet.103.051292","article-title":"Su TP. Intracellular dynamics of sigma-1 receptors (sigma(1) binding sites) in NG108-15 cells","volume":"306","author":"Hayashi","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1007\/s13311-018-00699-9_bib59","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1124\/jpet.103.051284","article-title":"Sigma-1 receptors (sigma(1) binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: roles in endoplasmic reticulum lipid compartmentalization and export","volume":"306","author":"Hayashi","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"12","key":"10.1007\/s13311-018-00699-9_bib60","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1523\/JNEUROSCI.21-12-04427.2001","article-title":"Forced limb-use effects on the behavioral and neurochemical effects of 6-hydroxydopamine","volume":"21","author":"Tillerson","year":"2001","journal-title":"The Journal of Neuroscience : The Official Journal of the Society for Neuroscience."},{"key":"10.1007\/s13311-018-00699-9_bib61","doi-asserted-by":"crossref","unstructured":"Robertson GS, Robertson HA.\u00a0Evidence that the substantia nigra is a site of action for L-DOPA. Neuroscience Letters. 1988;89(2):204\u20138.","DOI":"10.1016\/0304-3940(88)90382-5"},{"issue":"1","key":"10.1007\/s13311-018-00699-9_bib62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/0006-8993(93)90009-C","article-title":"Intranigral injections of SCH 23390 inhibit amphetamine-induced rotational behavior","volume":"623","author":"Yurek","year":"1993","journal-title":"Brain Research."},{"issue":"3","key":"10.1007\/s13311-018-00699-9_bib63","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3233\/JHD-170241","article-title":"Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington's Disease","volume":"6","author":"McGarry","year":"2017","journal-title":"Journal of Huntington's Disease."},{"issue":"11","key":"10.1007\/s13311-018-00699-9_bib64","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1111\/jcmm.12604","article-title":"Pridopidine, a dopamine stabilizer, improves motor performance and shows neuroprotective effects in Huntington disease R6\/2 mouse model","volume":"19","author":"Squitieri","year":"2015","journal-title":"Journal of Cellular and Molecular Medicine."}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13311-018-00699-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-00699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018895?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923018895?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-018-00699-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:12:49Z","timestamp":1761808369000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923018895"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1878747923018895"],"URL":"https:\/\/doi.org\/10.1007\/s13311-018-00699-9","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pridopidine Induces Functional Neurorestoration Via the Sigma-1 Receptor in a Mouse Model of Parkinson's Disease","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-018-00699-9","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2019 The authors. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}